CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing JACC Scientific Expert Panel Characterization of lesions undergoing ischemia-driven revascularization after complete revascularization versus culprit lesion only in patients with STEMI and multivessel disease - A DANAMI-3-PRIMULTI substudy Hemodynamic Response to Nitroprusside in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Ejection Fraction Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction Contemporary use of drug-coated balloons in coronary artery disease: Where are we now? 中国肺高血压诊断和治疗指南2018 Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS Comparison in prevalence, predictors, and clinical outcome of VSR versus FWR after acute myocardial infarction: The prospective, multicenter registry MOODY trial-heart rupture analysis Optimal medical therapy vs. coronary revascularization for patients presenting with chronic total occlusion: A meta-analysis of randomized controlled trials and propensity score adjusted studies Deficiency of GATA3-Positive Macrophages Improves Cardiac Function Following Myocardial Infarction or Pressure Overload Hypertrophy

Original Research

JOURNAL: Article Link

CIT2019 - 最新临床研究亮点

jiangxiao

CIT2019 - Research Spotlights
高危出血患者PCI治疗策略
LEADERS FREE Ⅱ Trail - 现有指南推荐非出血高风险的ACS患者接受PCI治疗后DAPT治疗时间持续12个月。高出血风险患者接受置入DES支架的PCI治疗后,可考虑将P2Y12抑制剂治疗缩短至 3~6个月(Ⅱb类推荐)。

2016年德国埃森大学医院Christoph K. Naber教授曾在EuroPCR上汇报了置入二代DES BioFreedom BA9药物涂层支架(Drug Coated Stent,DCS)介入治疗后进行1个月DAPT治疗相较于金属支架的有效性及安全性。
Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study
http://www.cbsmd.org/CBS2017CMS/scientificresearch.php?cid=127&id=1998&oldpage=1&ordertype=hits&page=1

LEADERS FREE研究对高出血风险因子的界定:
1) 年龄≥75岁;
2) PCI术后接受口服抗凝药物;
3) 无法耐受>30天的DAPT治疗;
4. 重要的手术相关指标包括长病变和复杂病变(即B2 & C型病变)。

预告CIT2019大会上,Naber教授将进一步汇报LEADERS FREE Ⅱ研究评估高出血风险患者药物涂层支架置入术后进行1个月DAPT的临床预后结果。
 
影像学指导PCI
ULTIMATE Trail - 在经诊断为无症状缺血、稳定或不稳定心绞痛或>24小时因胸痛入院的心肌梗死(包含STEMTI和NSTEMTI)的符合药物洗脱支架置入条件的全患者中证实了在理想药物洗脱支架置入的血管内超声(IVUS)指导下的DES置入相较于冠脉造影指导来说,不仅可辅助术者更准确地评估斑块内纤维、纤维脂质混合、坏死核和钙化等四种组织,优化置入效果,还可最终改善简单病变、甚至复杂病变PCI患者的预后。

理想的药物洗脱支架置入的IVUS标准,即:
1)DES植入后支架段最小管腔面积>5.0mm2,或大于90%的远端参考血管的最小管腔面积;
2)支架近端或远端5mm内的最大斑块负荷<50%;
3)无深达中层且存在长度超过3mm的夹层。

"Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug-Eluting Stent in All-Comers: The ULTIMATE trial"
http://www.cbsmd.org/CBS2017CMS/scientificresearch.php?cid=112&id=1254&oldpage=1&ordertype=posttime&page=1

"CBSMD专访——ULTIMATE研究者张俊杰谈IVUS之过去、现在和未来"
http://www.cbsmd.org/CBS2017CMS/newsshow.php?cid=4&id=1620

预告本届CIT2019大会上,张俊杰教授将进一步汇报ULTIMATE Trail亚组分析及荟萃分析结果。